The document discusses some of the unintended consequences of including patent-extracted and deuterated drug compounds in PubChem, including increased complexity and confusion for users. Specifically, it notes that the same marketed drug like Rosuvastatin is represented by over 15 compound IDs in PubChem due to different deuterated forms extracted from patents. This "multiplexing" of compound IDs can mess up search results and integration with other databases. While filtering out such compounds may be ideal, it is difficult to distinguish experimental from hypothetical structures in patents. Better flags or clustering of related compounds could help address the issues.